Business Insider24d
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of ...
Business Insider24d
Septerna discontinues SEP-786 Phase 1 clinical trial in hypoparathyroidism
Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of ...
The Straits Times29d
$788m mixed-use development to be built near Johor RTS station linking to Woodlands
JOHOR BAHRU-A RM2.6 billion (S$788 million) development including a mall topped by four towers is being planned at the Johor Bahru terminus of the upcoming Johor Bahru-Singapore Rapid Transit ...
Asia One1mon
Malaysia to build $786 million integrated property comprising mall, apartments and hotel next to JB-Singapore RTS Link station
The RM2.6 billion (S$786 million) development is a strategic partnership between Malaysia's Mass Rapid Transit Corporation (MRT Corp) and Malaysian conglomerate Sunway Group. Both parties signed ...